UBS Group Increases Merck & Co., Inc. (NYSE:MRK) Price Target to $175.00

Merck & Co., Inc. (NYSE:MRK) had its price objective upped by UBS Group from $145.00 to $175.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective would suggest a potential upside of 15.34% from the company’s current price.

Other analysts also recently issued research reports about the company. Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Barclays increased their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company raised their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.70.

Merck & Co., Inc. Trading Down 0.3%

Shares of MRK stock traded down $0.47 on Thursday, reaching $151.73. 6,239,130 shares of the company’s stock were exchanged, compared to its average volume of 10,764,729. The company’s fifty day simple moving average is $126.86 and its 200 day simple moving average is $120.74. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $153.50. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $374.34 billion, a PE ratio of 121.38, a P/E/G ratio of 5.83 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares of the company’s stock, valued at $14,501,282.21. This trade represents a 9.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds have recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth $26,000. High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized mRNA cancer vaccine, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a Phase 3 melanoma trial. The regimen significantly extended recurrence-free survival and reduced the risk of cancer spreading compared with Keytruda alone—the first positive late-stage result for an mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The results strengthen Merck’s longer-term oncology pipeline and could help offset concerns about Keytruda’s expected patent expiration later this decade. The companies see potential use in thousands of high-risk melanoma patients, subject to additional data and regulatory approval targeted for 2027, while related trials are evaluating other cancers. Why this mRNA cancer vaccine is raising new treatment hope
• Positive Sentiment: Morgan Stanley upgraded MRK from “equal weight” to “overweight” and raised its price target to $179 from $116, implying substantial potential upside based on the reported valuation. Merck analyst upgrade
• Neutral Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating but lifted its target to $150 from $142, indicating limited near-term upside and a more cautious view of the vaccine opportunity. Royal Bank of Canada rating update
• Neutral Sentiment: Unusually heavy options activity, including a sharp increase in call purchases, suggests heightened speculative interest following the trial announcement, but does not necessarily indicate sustained fundamental demand.
• Negative Sentiment: Jefferies downgraded Merck from “strong-buy” to “hold,” reflecting potential profit-taking and uncertainty about the vaccine’s eventual approval, commercial adoption, pricing, and contribution relative to Keytruda’s mature revenue base. Jefferies rating update

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.